| Literature DB >> 25510839 |
Jay R Hoffman1, Geva Landau, Jeffrey R Stout, Mattan W Hoffman, Nurit Shavit, Philip Rosen, Daniel S Moran, David H Fukuda, Ilan Shelef, Erez Carmom, Ishay Ostfeld.
Abstract
The purpose of this study was to examine the effect of β-alanine (BA) ingestion on tissue carnosine levels and the impact such changes would have on combat specific activity. Eighteen soldiers (19.9 ± 0.8 year) from an elite combat unit were randomly assigned to either a BA or placebo (PL) group. Before and following a 30-day supplementation period carnosine content of the gastrocnemius muscle and brain was determined by proton magnetic resonance spectroscopy. During each testing session, participants performed military relevant tasks that included a 2.5 km run, a 1-min sprint, 50-m casualty carry, repeated 30-m sprints with target shooting, and a 2-min serial subtraction test (SST) to assess cognitive function under stressful conditions. A significant elevation (p = 0.048) in muscle carnosine content was noted in BA compared to PL. Changes in muscle carnosine content was correlated to changes in fatigue rate (r = 0.633, p = 0.06). No changes (p = 0.607) were observed in brain carnosine content. Following supplementation, no differences were noted in 2.5 km run, 1-min sprint, repeated sprint, or marksmanship performance, but participants in BA significantly (p = 0.044) improved their time for the 50-m casualty carry and increased their performance (p = 0.022) in the SST compared to PL. In summary, 30-days of BA ingestion can increase muscle carnosine content and improve aspects of military specific performance. Although cognitive performance was significantly greater in participants consuming BA compared to placebo, current study methods were unable to detect any change in brain carnosine levels, thus, the precise mechanism underlying these effects remains elusive.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25510839 PMCID: PMC4326648 DOI: 10.1007/s00726-014-1896-7
Source DB: PubMed Journal: Amino Acids ISSN: 0939-4451 Impact factor: 3.520
Fig. 1Changes in ∆ carnosine content in the gastrocnemius. All data are reported as mean ± SD. *Significant difference (p < 0.05) between groups, BA β-alanine, PL placebo
Performance variables during the 2.5 km run
| Variable | Group | PRE | POST |
|
|---|---|---|---|---|
| Time (s) | BA | 624 ± 22.6 | 629 ± 23.8 | 0.866 |
| PL | 633 ± 25.3 | 609 ± 36.4 | ||
| Average Velocity (ms−1) | BA | 3.97 ± 0.17 | 4.09 ± 0.25 | 0.944 |
| PL | 3.94 ± 0.14 | 4.05 ± 0.24 | ||
| Average heart rate (beats min−1) | BA | 156.8 ± 15.5 | 165.7 ± 6.1 | 0.122 |
| PL | 162.1 ± 11.7 | 159.3 ± 11.4 | ||
| Distance run at low intensity (%) | BA | 12.3 ± 12.0 | 10.7 ± 14.0 | 0.873 |
| PL | 15.2 ± 12.6 | 12.3 ± 14.9 | ||
| Distance run at moderate intensity (%) | BA | 69.8 ± 12.1 | 65.1 ± 14.8 | 0.502 |
| PL | 71.1 ± 10.9 | 63.7 ± 14.7 | ||
| Distance run at high intensity (%) | BA | 18.4 ± 12.4 | 23.9 ± 20.1 | 0.645 |
| PL | 13.3 ± 9.2 | 23.9 ± 20.2 |
All data are reported as mean ± SD
BA β-alanine group, PL placebo group
Performance variables during the sprint protocols and serial subtraction test
| Assessment | Variable | Group | PRE | POST |
|
|---|---|---|---|---|---|
| 1-min sprint | Peak velocity (ms−1) | BA | 6.68 ± 0.36 | 6.57 ± 0.18 | 0.354 |
| PL | 6.71 ± 0.48 | 6.77 ± 0.43 | |||
| Average velocity (ms−1) | BA | 5.21 ± 0.28 | 5.09 ± 0.36 | 0.535 | |
| PL | 5.19 ± 0.33 | 5.15 ± 0.29 | |||
| Fatigue rate (%) | BA | 32.5 ± 5.5 | 30.9 ± 6.7 | 0.893 | |
| PL | 32.2 ± 7.1 | 30.1 ± 5.4 | |||
| Distance run at 90 % peak velocity | BA | 69.5 ± 4.1 | 58.5 ± 7.7 | 0.199 | |
| PL | 66.0 ± 6.0 | 60.8 ± 7.5 | |||
| Repeat 30-m sprints | Average sprint time (s) | BA | 7.42 ± 0.24 | 8.00 ± 0.29 | 0.780 |
| PL | 7.43 ± 0.26 | 8.00 ± 0.22 | |||
| Fatigue rate (%) | BA | 91.6 ± 4.8 | 91.8 ± 3.0 | 0.432 | |
| PL | 93.8 ± 1.8 | 92.4 ± 3.2 | |||
| 50-m casualty carry | Time (s) | BA | 15.60 ± 1.16 | 15.34 ± 0.97 | 0.044 |
| PL | 14.64 ± 0.73 | 14.86 ± 0.85 | |||
| Serial subtraction | Number of correct responses (#) | BA | 27.1 ± 8.2 | 31.9 ± 7.9 | 0.022 |
| PL | 26.0 ± 6.1 | 26.4 ± 8.5 |
All data are reported as mean ± SD
BA β-alanine group, PL placebo group
Fig. 2Changes in ∆ 50-m Casualty Carry. All data are reported as mean ± SD. *Significant difference (p < 0.05) between groups, BA β-alanine, PL placebo
Fig. 3Changes in ∆ serial subtraction test. All data are reported as mean ± SD. *Significant difference (p < 0.05) between groups, BA β-alanine, PL placebo